Monoclonal Antibody Market

Table of Content

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Introduction

2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative

2.4.2.3. Advantages

2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions

2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Hospitals

2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity

2.4.3. Analytical Tools and Databases

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach

3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)

3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis

3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation

3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Monoclonal Antibody
6.2.1. Properties of Monoclonal Antibody
6.2.2. Key Applications of Monoclonal Antibody
6.2.3. Challenges Associated with Manufacturing of Monoclonal Antibody

6.3. Future Perspective

7. MARKET COMPETITIVE LANDSCAPE
7.1. Chapter Overview
7.2. Monoclonal Antibody Providers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters

7.2.4. Monoclonal Antibody Providers: Overall Market Landscape
7.2.4.1. Analysis by Source Type
7.2.4.2. Analysis by Production Method Type
7.2.4.3. Analysis by Application Area
7.2.4.4. Analysis by End User

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodologies

8.4. Company Competitiveness Analysis: Monoclonal Antibody Providers
8.4.1. Monoclonal Antibody Providers Based in North America (Peer Group 1)
8.4.2. Monoclonal Antibody Providers Based in Europe (Peer Group 2)
8.4.3. Monoclonal Antibody Providers Based in Asia-Pacific (Peer Group 3)

8.5. Key Findings

9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Amgen (US)
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Service / Product Portfolio
9.2.4. Recent Developments and Future Outlook

9.3. Abbott Laboratories (US)
9.4. AstraZeneca (UK)
9.5. Bayer (Germany)
9.6. Bristol Myers Squibb (US)
9.7. Biogen (US)
9.8. Daiichi Sankyo Company (Japan)
9.9. Eli Lilly (US)
9.10. GlaxoSmithKline (UK)
9.11. Johnson & Johnson (US)
9.12. Merck (US)
9.13. Novartis (Switzerland)
9.14. Novo Nordisk (Denmark)
9.15. Pfizer (US)
9.16. Roche (Switzerland)
9.17. Sanofi (France)
9.18. Thermo Fisher Scientific (US)
9.19. Viatris (US)

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models

10.3. Monoclonal Antibody Providers: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Type of Product
10.3.5. Analysis by Type of Partnership and Type of Product
10.3.6. Analysis of Amount Invested Via Acquisitions
10.3.7. Analysis by Type of Partner
10.3.8. Most Active Players: Analysis by Number of Partnerships

10.3.9. Analysis by Geography
10.3.9.1. Intracontinental and Intercontinental Deals
10.3.9.2. International and Local Deals

11. MERGERS AND ACQUISITIONS
11.1. Chapter Overview
11.2. Merger and Acquisition Models

11.3. Monoclonal Antibody Providers: Mergers and Acquisitions
11.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
11.3.2. Analysis by Type of Acquisition

11.3.3. Analysis by Geography
11.3.3.1. Local and International Mergers and Acquisitions
11.3.3.2. Intracontinental and Intercontinental Mergers and Acquisitions
11.3.3.3. Year-wise Trend in North America, Europe, and Asia-Pacific

11.3.4. Most Active Acquirers: Analysis by Number of Acquisitions
11.3.5. Analysis by Key Value Drivers
11.3.6. Analysis by Year of Acquisition and Key Value Drivers
11.3.7. Analysis by Type of Product
11.3.8. Analysis by Key Value Drivers and Type of Product

11.4. Key Acquisitions: Deal Multiples
11.4.1. Year-wise Trend of Deal Multiple Amount

12. CLINICAL TRIALS ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology

12.3. Monoclonal Antibody: Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
12.3.3. Analysis by Trial Phase
12.3.4. Analysis of Number of Patients Enrolled by Trial Phase
12.3.5. Analysis by Trial Status
12.3.6. Analysis by Trial Registration Year and Trial Status
12.3.7. Analysis by Target Patient Population
12.3.8. Analysis by Patient Gender

12.3.9. Analysis by Study Design
12.3.9.1. Analysis by Type of Allocation
12.3.9.2. Analysis by Type of Intervention Model
12.3.9.3. Analysis by Type of Masking
12.3.9.4. Analysis by Trial Purpose

12.3.10. Analysis by Type of Sponsor / Collaborator
12.3.11. Leading Players: Analysis by Number of Clinical Trials

12.3.12. Analysis by Geography
12.3.12.1. Analysis of Clinical Trials by Geography
12.3.12.2. Analysis of Clinical Trials by Geography and Trial Status
12.3.12.3. Analysis of Patients Enrolled by Geography and Trial Status

13. MARKET IMPACT ANALYSIS
13.1. Chapter Overview
13.2. Market Drivers
13.3. Market Restraints
13.4. Market Opportunities
13.5. Market Challenges
13.6. Conclusion

14. GLOBAL MONOCLONAL ANTIBODY MARKET
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Trends Disruption Impacting Market
14.4. Global Monoclonal Antibody, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

14.5. Multivariate Scenario Analysis
14.5.1. Conservative Scenario
14.5.2. Optimistic Scenario

14.6. Key Market Segmentations

15. MARKET OPPORTUNITIES BASED ON TYPE OF SOURCE
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Revenue Shift Analysis
15.4. Market Movement Analysis
15.5. Penetration-Growth (P-G) Matrix
15.6. Monoclonal Antibody Market Murine: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
15.7. Monoclonal Antibody Market for Chimeric: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
15.8. Monoclonal Antibody Market for Humanized: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
15.9. Monoclonal Antibody Market for Human: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
15.10. Data Triangulation and Validation

16. MARKET OPPORTUNITIES BASED ON TYPE OF PRODUCTION METHOD
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Revenue Shift Analysis
16.4. Market Movement Analysis
16.5. Penetration-Growth (P-G) Matrix
16.6. Monoclonal Antibody Market for In Vivo: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.7. Monoclonal Antibody Market for In Vitro: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
16.8. Data Triangulation and Validation

17. MARKET OPPORTUNITIES BASED ON APPLICATION AREA
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Revenue Shift Analysis
17.4. Market Movement Analysis
17.5. Penetration-Growth (P-G) Matrix
17.6. Monoclonal Antibody Market for Oncology: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.7. Monoclonal Antibody Market for Autoimmune Diseases: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.8. Monoclonal Antibody Market for Infectious Diseases: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.9. Monoclonal Antibody Market for Neurological Diseases: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.10. Monoclonal Antibody Market for Other End Users: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
17.11. Data Triangulation and Validation

18. MARKET OPPORTUNITIES BASED ON DISTRIBUTION CHANNEL
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Revenue Shift Analysis
18.4. Market Movement Analysis
18.5. Penetration-Growth (P-G) Matrix
18.6. Monoclonal Antibody Market for Hospital Pharmacy: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
18.7. Monoclonal Antibody Market for Specialty Centers: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
18.8. Monoclonal Antibody Market for Others: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
18.9. Data Triangulation and Validation

19. MARKET OPPORTUNITIES BASED ON END USER
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Revenue Shift Analysis
19.4. Market Movement Analysis
19.5. Penetration-Growth (P-G) Matrix
19.6. Monoclonal Antibody Market for Hospitals: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.7. Monoclonal Antibody Market for Online Pharmacy: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.8. Monoclonal Antibody Market for Retail Pharmacy: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
19.9. Data Triangulation and Validation

20. MARKET OPPORTUNITIES FOR MONOCLONAL ANTIBODY IN NORTH AMERICA
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix

20.6. Monoclonal Antibody Market in North America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.1. Monoclonal Antibody Market in the US: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.2. Monoclonal Antibody Market in Canada: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
20.6.3. Monoclonal Antibody Market in Mexico: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

20.7. Data Triangulation and Validation

21. MARKET OPPORTUNITIES FOR MONOCLONAL ANTIBODY IN EUROPE
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix

21.6. Monoclonal Antibody Market in Europe: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.1. Monoclonal Antibody Market in France: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.2. Monoclonal Antibody Market in Germany: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.3. Monoclonal Antibody Market in Italy: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.4. Monoclonal Antibody Market in Spain: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.5. Monoclonal Antibody Market in the UK: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
21.6.6. Monoclonal Antibody Market in Rest of Europe: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

21.7. Data Triangulation and Validation

22. MARKET OPPORTUNITIES FOR MONOCLONAL ANTIBODY IN ASIA-PACIFIC
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix

22.6. Monoclonal Antibody Market in Asia-Pacific: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
22.6.1. Monoclonal Antibody Market in China: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
22.6.2. Monoclonal Antibody Market in India: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
22.6.3. Monoclonal Antibody Market in Japan: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
22.6.4. Monoclonal Antibody Market in South Korea: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
22.6.5. Monoclonal Antibody Market in Rest of the Asia-Pacific: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

22.7. Data Triangulation and Validation

23. MARKET OPPORTUNITIES FOR MONOCLONAL ANTIBODY IN MIDDLE EAST AND NORTH AFRICA (MENA)
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Revenue Shift Analysis
23.4. Market Movement Analysis
23.5. Penetration-Growth (P-G) Matrix

23.6. Monoclonal Antibody Market in Middle East and North Africa (MENA): Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
23.6.1. Monoclonal Antibody Market in Egypt: Historical Trends (Since 2019) and Forecasted Estimates (Till 205)
23.6.2. Monoclonal Antibody Market in Saudi Arabia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
23.6.3. Monoclonal Antibody Market in United Arab Emirates (UAE): Historical Trends and Forecasted Estimates (Till 2035)

23.7. Data Triangulation and Validation

24. MARKET OPPORTUNITIES FOR MONOCLONAL ANTIBODY IN LATIN AMERICA
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Revenue Shift Analysis
24.4. Market Movement Analysis
24.5. Penetration-Growth (P-G) Matrix

24.6. Monoclonal Antibody Market in Latin America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
24.6.1. Monoclonal Antibody Market in Argentina: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
24.6.2. Monoclonal Antibody Market in Brazil: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

24.7. Data Triangulation and Validation

25. TABULATED DATA

26. LIST OF COMPANIES AND ORGANIZATIONS

27. CUSTOMIZATION OPPORTUNITIES

28. ROOTS SUBSCRIPTION SERVICES

29. AUTHOR DETAIL